MedWatch

Lundbeck EVP aims for phase III next year after new PTSD data

Although Lundbeck only partly succeeded in a new phase II study with a combination therapy against PTSD, the executive vice president for Research and Development still sees a potential in the indication and expects to initiate phase III next year.

Anders Gersel Pedersen, CSO in Lundbeck. | Foto: PR

Lundbeck is aiming for phase III in 2019 after the Danish drug group and its Japanese partner Otsuka received phase II data for a trial combining the drug brexpiprazole and Pfizer's Zoloft for treatment of Post-Traumatic Stress Disorder (PTSD).

This is according to Lundbeck's executive vice president for Research and Development, Anders Gersel Pedersen.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier